Cost of disease
Verma, O.P.
Journal of the Indian Medical Association 65(2): 60-64
1975
ISSN/ISBN: 0019-5847 PMID: 811711 Document Number: 93171
Document emailed within 1 workday
Related Documents
Kawalec, P.ł; Holko, P.ła.; Szkultecka-Debek, M.; Paszulewicz, A.; Boratyńska, M.; Głyda, M.; Ignacak, E.; Maks, J.; Russel-Szymczyk, M.; Kaweczyńska-Lasoń, A. 2013: The evaluation of cost-effectiveness and cost-utility of valganciclovir for the prophylaxis of cytomegalovirus disease to 200 days after kidney transplantation Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego 34(204): 332-338Shade, S.B.; Kevany, S.; Onono, M.; Ochieng, G.; Steinfeld, R.L.; Grossman, D.; Newmann, S.J.; Blat, C.; Bukusi, E.A.; Cohen, C.R. 2013: Cost, cost-efficiency and cost-effectiveness of integrated family planning and HIV services Aids 27(Suppl 1): S87-S92
Bohácek, N. 1972: Economic cost of mental disease? Lijecnicki Vjesnik 94(9): 466-468
Rikli, A.E.; Hall, L.; Frazier, F. 1978: Cost and technology: end-stage renal disease Clinical Engineering 6(2): 17-19
O'Neill, S. 1987: Asbestos induced disease--the cost of containment Irish Medical Journal 80(3): 78-79
Hunink, M.G.; Wong, J.B.; Donaldson, M.C.; Meyerovitz, M.F.; de Vries, J.; Harrington, D.P. 1995: Revascularization for femoropopliteal disease. a decision and cost-effectiveness analysis JAMA 274(2): 165-171
Valladares, A.; Dilla, T.; Sacristán, J.A. 2009: Depression: a social mortgage. Latest advances in knowledge of the cost of the disease Actas Espanolas de Psiquiatria 37(1): 49-53
Arj-ong, S.; Chotivitayatarakorn, P.; Lertsapcharoen, P.; Khongphatthanayothin, A.; Thisyakorn, C. 2003: A cost-benefit analysis of intravenous immunoglobulin treatment in children with Kawasaki disease Journal of the Medical Association of Thailand 86(Suppl): S179-S188
Maurel, F.; Lilliu, H.; Le-Pen, C. 2001: Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease Revue Neurologique (Paris) 157(5): 507-514
Coleman, R.E. 1995: Clinically available evaluation of bone disease in breast cancer--validity and cost effectiveness Canadian Journal of Oncology 5(Suppl 1): 69-79
Dal Negro, R.; Berto, P.; Tognella, S.; Quareni, L. 2002: Cost-of-illness of lung disease in the TriVeneto Region, Italy: the GOLD Study Monaldi Archives for Chest Disease 57(1): 3-9
Lindbloom, E.J.; Eaton, L.J. 2002: Cost effectiveness of aspirin vs clopidogrel for secondary prevention of coronary heart disease Journal of Family Practice 51(9): 789
Nakao, M.; Watanabe, H. 1987: Cost-benefit effect of mass screening for prostatic disease on national economy Hinyokika Kiyo. Acta Urologica Japonica 33(10): 1542-1546
Mielck, A. 1988: Cost-effectiveness and cost-benefit approaches in programs designed to prevent AIDS Aids and Public Policy Journal 3(3): 19-22
Kahn, J.G.; Jiwani, A.; Gomez, G.B.; Hawkes, S.J.; Chesson, H.W.; Broutet, N.; Kamb, M.L.; Newman, L.M. 2014: The cost and cost-effectiveness of scaling up screening and treatment of syphilis in pregnancy: a model PLOS one 9(1): E87510
Hudecková, H.; Straka, S.; Szilágyiová, M.; Avdicová, M.; Rusnáková, S. 2002: Cost effectiveness and cost benefit of viral hepatitis B vaccination in the Slovak Republic Central European Journal of Public Health 10(4): 146-148
Drummond, M.F. 1985: Survey of cost-effectiveness and cost-benefit analyses in industrialized countries World Health Statistics Quarterly. Rapport Trimestriel de Statistiques Sanitaires Mondiales 38(4): 383-401
Wilson, L. 2008: The cost of errors. Medicare's new policy could cost the average hospital $23,772: study Modern Healthcare Suppl: 8-9
Tremblay, J. 1980: Prescription drugs and the aged: cost-free and cost-containment measures L'Union Medicale du Canada 109(3): 414-420
Deirdre Wulf 1981: Cost-Benefit and Cost-Effectiveness Analysis for Family Planning Programs International Family Planning Perspectives 7(4): 141-144